UGT1A1, UGT1A6 and UGT1A7 Genetic Analysis: Repercussion for Irinotecan Pharmacogenetics in the São Miguel Island Population (Azores, Portugal)

By Pacheco Paula R.   Brilhante Maria J.   Ballart Cristina   Sigalat Francesc   Polena Helena   Cabral Rita   Branco Claudia C.   Mota-Vieira Luisa  

Molecular Diagnosis & Therapy, Vol. 13, Iss. 4, 2009-08 ,pp. : 261-268

Adis International

Access to resources Recommend Favorite

A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI

By  

Oncology, Vol. 88, Iss. 3, 2014-11 ,pp. : 164-172

Karger

Access to resources Recommend Favorite

A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1,*1/*6 or *1/*28

By  

Oncology, Vol. 82, Iss. 4, 2012-04 ,pp. : 242-248

Karger

Access to resources Recommend Favorite

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 290-297

Karger

Access to resources Recommend Favorite

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 581-588

John Wiley & Sons Inc

Access to resources Recommend Favorite